<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858831</url>
  </required_header>
  <id_info>
    <org_study_id>116441</org_study_id>
    <nct_id>NCT01858831</nct_id>
  </id_info>
  <brief_title>Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension</brief_title>
  <official_title>Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a single-center, phase I, randomized, open, in fed condition, parallel,&#xD;
      single dose study to evaluate the pharmacokinetics and the safety, tolerability of&#xD;
      Atovaquone/proguanil combination tablets and atovaquone suspension in Japanese healthy male&#xD;
      subjects.&#xD;
&#xD;
      Serial blood samples will be collected for the determination of the plasma concentration of&#xD;
      atovaquone, proguanil and cycloguanil after dosing of atovaquone 1000mg/proguanil 400 mg and&#xD;
      the plasma atovaquone concentration of atovaquone 750 and 1500 mg. Safety assessments will be&#xD;
      performed for each treatment group.&#xD;
&#xD;
      CYP2C19 contribute to proguanil metabolism. CYP2C19 genotype will be determined in&#xD;
      atovaquone/proguanil dosing group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma atovaquone concentration</measure>
    <time_frame>pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma proguanil concentration</measure>
    <time_frame>pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma cycloguanil concentration</measure>
    <time_frame>pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 336h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>at pre-dose, 4, 24, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG findings</measure>
    <time_frame>at pre-dose, 4, 72, 168 and 336 h post-dose</time_frame>
    <description>Change at 4, 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory</measure>
    <time_frame>at pre-dose, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>at pre-dose, 4, 24, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart rate</measure>
    <time_frame>at pre-dose, 4, 24, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 4, 24, 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hematology values</measure>
    <time_frame>at pre-dose, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry values</measure>
    <time_frame>at pre-dose, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinalysis values</measure>
    <time_frame>at pre-dose, 72, 168 and 336 h post-dose</time_frame>
    <description>Change values at 72, 168 and 336 h post-dose from baseline (pre-dose)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Atovaquone/proguanil HCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atovaquone/proguanil HCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atovaquone 750 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atovaquone 750 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atovaquone 1500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atovaquone 1500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone/proguanil HCL</intervention_name>
    <description>Atovaquone/proguanil HCL</description>
    <arm_group_label>Atovaquone/proguanil HCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone</intervention_name>
    <description>Atovaquone</description>
    <arm_group_label>Atovaquone 1500 mg</arm_group_label>
    <arm_group_label>Atovaquone 750 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as defined as being free from clinically significant illness or disease as&#xD;
             determined by a responsible and experienced physician, based on a medical evaluation&#xD;
             including medical history, physical examination, vital sign, laboratory tests and ECG.&#xD;
&#xD;
          -  Japanese healthy male between 20 and 55 years of age inclusive, at the time of signing&#xD;
             the informed consent.&#xD;
&#xD;
          -  Body weight =&gt; 50 kg and BMI within the range 18.5- 25 kg/m2&#xD;
&#xD;
          -  Non-smoker or ex-smoker having ceased smoking for at least 6 months. (inclusive).&#xD;
&#xD;
          -  ALT, alkaline phosphatase and bilirubin below the upper limit of normal (ULN)&#xD;
&#xD;
          -  Single QTcB&lt; 450 msec.&#xD;
&#xD;
          -  Vital sign within the following ranges; Systolic blood pressure: &lt; 90 mmHg or &gt; 140&#xD;
             mmHg, Diastolic blood pressure: &lt; 45 mmHg or &gt; 90 mmHg, Plus rate: &lt; 45 bpm or &gt; 100&#xD;
             bpm, Body temperature: 37.5 C&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive results of syphilis, HBs antigen, HCV antibody, HIV antibody and HTLV-1&#xD;
             antibody at the time of screening.&#xD;
&#xD;
          -  History of any cardiac diseases irrespective of with or without symptom.&#xD;
&#xD;
          -  An episode of cardiac syncope within one year before screening period.&#xD;
&#xD;
          -  History/evidence of clinically significant pulmonary diseases and&#xD;
             hyper/hypo-thyroidism.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug screen.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding, on average, 14 drinks/week for men&#xD;
             (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80&#xD;
             proof distilled spirits) within 6 months of screening.&#xD;
&#xD;
          -  The subject had participated in a clinical study or post-marketing study with an&#xD;
             investigational or a non-investigational product during the previous 4 months&#xD;
             preceding the administration of study medication of this study.&#xD;
&#xD;
          -  The subject had participated in a clinical study or post-marketing study with an&#xD;
             investigational or a non-investigational product during the previous 4 months&#xD;
             preceding the administration of study medication of this study.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Unable to refrain from the use of alcohol, prescription or non-prescription drugs,&#xD;
             including vitamins, herbal and dietary supplements within 14 days or 5 half-lives&#xD;
             (whichever is longer) prior to the first dose of study medication.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy excluding pollen allergy without current symptoms.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 400 mL within a 4 month or 200 mL within 2 month.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

